A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With Dose Expansion Cohorts in Patients With Advanced Solid Tumors
Latest Information Update: 06 Mar 2025
At a glance
- Drugs DFP 13318 (Primary) ; Tuvusertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms POP-ART
- 03 Mar 2025 Planned primary completion date changed from 23 Sep 2027 to 23 Sep 2028.
- 10 Feb 2025 Planned End Date changed from 15 Feb 2029 to 23 Sep 2029.
- 10 Feb 2025 Planned primary completion date changed from 15 Jun 2025 to 23 Sep 2027.